Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

× No keyword cloud information.

53 in total

1. The value of branded proton pump inhibitors: formulary considerations.

Authors: David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal: P T Date: 2011-07

Review 2. The risks of PPI therapy.

Authors: Paul Moayyedi; Grigorios I Leontiadis
Journal: Nat Rev Gastroenterol Hepatol Date: 2012-02-14 Impact factor: 46.802

3. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.

Authors: Johanne Brooks; Richard Warburton; Ian L P Beales
Journal: Ther Adv Chronic Dis Date: 2013-09 Impact factor: 5.091

4. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.

Authors: Wayne A Ray; Cecilia P Chung; Katherine T Murray; Walter E Smalley; James R Daugherty; William D Dupont; C Michael Stein
Journal: Gastroenterology Date: 2016-09-14 Impact factor: 22.682

5. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects.

Authors: K Iijima; T Koike; N Ara; K Nakagawa; Y Kondo; K Uno; W Hatta; N Asano; A Imatani; T Shimosegawa
Journal: J Gastroenterol Date: 2014-06-22 Impact factor: 7.527

10. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

Authors: Nobuyoshi Takabayashi; Kyoko Murata; Shiro Tanaka; Koji Kawakami
Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

1. The value of branded proton pump inhibitors: formulary considerations.

Review 2. The risks of PPI therapy.

3. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.

4. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.

5. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects.

Review 6. Managing adverse effects and drug-drug interactions of antiplatelet agents.

7. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016.

8. [Long-term use of proton pump inhibitors: who needs prophylaxis?].

9. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

10. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.